Summary
Using human umbilical cord endothelial cell cultures and a modified 3HTdR uptake technique, endothelial cell cytotoxic activity (ECA) has been demonstrated in sera of 95/130 patients with progressive systemic sclerosis (PSS), 14/20 patients with Raynaud syndrome (RS), 52/153 rheumatoid arthritis (RA), and 47/113 systemic lupus erythematosus (SLE) sera. ECA could be enriched by gel filtration from PSS sera in a molecular weight range of 5 k daltons. ECA was partially associated with serum proteins, mainly in the albumin containing fraction, albeit at a lower level of activity. In PSS, no relationship of ECA to the type of skin involvement was observed. ECA appears to be a low molecular weight mediator of, as yet, unknown origin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Norton WL, Nardo JM (1970) Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73:317–324
Sinclair RA, Antonovych TT, Mostofi FK (1976) Renal proliferative arteriopathies and associated glomerular changes. Hum Pathol 7:565–588
Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161–170
Fleischmajer R, Perlish JS, West WP (1977) Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 113:1661–1666
Fleischmajer R, Perlish JS, Duncan M (1983) Scleroderma. A model for fibrosis. Arch Dermatol 119:957–962
Maricq HR, Spencer-Green G, LeRoy EC (1976) Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 61:862–870
Kahaleh MB, Sherer GK, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326–1335
Kahaleh MB, Osborne I, LeRoy EC (1981) Increased factor VIII/von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 94:962–964
Shanahan WR Jr, Korn JH (1982) Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum 25:1391–1395
Meyer O, Haim T, Dryll A, Lansaman J, Ryckewaert A (1983) Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 1:29–34
Cohen S, Johnsen AR, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Arthritis Rheum 26:170–178
Kahaleh MB, Le Roy EL (1983) Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 101:533–560
Jayson MJV (1983) Systemic sclerosis — a microvascular disorder? J R Soc Med 76:635–642
Deicher H, Mielke H, Daniel W, Drommer W, Fischer M, Fritsch R, Müller-Vahl H, Sybrecht G, Weißbarth E (1981) Studies on the vasculopathy of rheumatoid arthritis and its relation to systemic rheumatoid disease, In: Deicher H, Schulz LC1 (eds) Arthritis — Models and mechanisms. Springer, Berlin Heidelberg New York
Luderschmidt Ch, Kaulertz I, König G, Leisner B (1984) Progressive systemische Sklerose. Klinisches Spektrum und prognostische Parameter von 131 Patienten. Dtsch Med Wochenschr 37:1389–1397
Gospodarowicz D, Bialecki H, Greenburg G (1978) Purification of the fibroblast growth factor activity from bovine brain. J Biol Chem 253:3736–3743
Drenk F, Deicher H (in preparation)
Raines EW, Ross R (1982) Platelet-derived growth factor. High yield purification and evidence for multiple forms. J Biol Chem 257:5154–5160
LeRoy EC, Mercurio SM, Kahaleh MB (1982) A fibroblast mitogen with protease activity in scleroderma serum. Arthritis Rheum 25 (Suppl):38
Hooks JJ, Mousopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5–8
Cohen MC, Picciano PT, Douglas WJ, Yoshiba T, Kreutzer DL, Cohen S (1982) Migration inhibition of endothelial cells by lymphokine-containing supernatants. Science 215:301–303
Ninnemann JL, Stockland AE (1984) Participation of prostaglandin E in immunosuppression following thermal injury. J Trauma 24:201–207
Zeller J, Weißbarth E, Baruth B, Mielke H, Deicher H (1982) Serotonin contents of platelts in inflammatory rheumatic disorders. Arthritis Rheum 26:110–115
Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelet aggregates and beta thromboglobulin in scleroderma. Ann Intern Med 96:610–613
Hope W, Martin TJ, Chesterman CN, Morgan FJ (1979) Human β-thromboglobulin inhibits PGT2 production and binds to a specific site in bovine aortic endothelial cells. Nature 282:210–212
Boucek RJ, Speropoulos AJ, Noble NL (1972) Serotonin and ribonucleic acid and collagen metabolism of fibroblasts in vitro. Proc Soc Exp Biol Med 140:599–603
Boucek RJ, Noble NL (1973) Histamine, norepinephrine and bradykinin stimulation of fibroblast growth and modification of serotonin response. Proc Soc Exp Biol Med 144:929–933
Krakauer RS, Sundeen J, Sauder DN, Scherbel A (1981) Abnormalities in immunregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function. Arch Dermatol 177:80–82
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. F. Hartmann, the founder of the Department of Medicine and Dermatology, Medizinische Hochschule Hannover
Rights and permissions
About this article
Cite this article
Drenk, F., Mensing, H., Serbin, A. et al. Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 5, 259–263 (1985). https://doi.org/10.1007/BF00541353
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541353